vs
Bioceres Crop Solutions Corp.（BIOX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是Bioceres Crop Solutions Corp.的1.9倍（$151.1M vs $77.6M），STURM RUGER & CO INC同比增速更快（3.6% vs -16.8%），过去两年STURM RUGER & CO INC的营收复合增速更高（5.1% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
BIOX vs RGR — 直观对比
营收规模更大
RGR
是对方的1.9倍
$77.6M
营收增速更快
RGR
高出20.4%
-16.8%
两年增速更快
RGR
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $151.1M |
| 净利润 | $-7.4M | — |
| 毛利率 | 46.8% | 17.8% |
| 营业利润率 | 9.3% | 2.3% |
| 净利率 | -9.6% | — |
| 营收同比 | -16.8% | 3.6% |
| 净利润同比 | -20.2% | — |
| 每股收益（稀释后） | $-0.12 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXRGR
| Q4 25 | — | $151.1M | ||
| Q3 25 | $77.6M | $126.8M | ||
| Q2 25 | — | $132.5M | ||
| Q1 25 | $60.6M | $135.7M | ||
| Q4 24 | $98.8M | $145.8M | ||
| Q3 24 | $93.3M | $122.3M | ||
| Q2 24 | — | $130.8M | ||
| Q1 24 | $84.0M | $136.8M |
净利润BIOXRGR
| Q4 25 | — | — | ||
| Q3 25 | $-7.4M | $1.6M | ||
| Q2 25 | — | $-17.2M | ||
| Q1 25 | $-1.6M | $7.8M | ||
| Q4 24 | $605.2K | — | ||
| Q3 24 | $-6.2M | $4.7M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | $9.8M | $7.1M |
毛利率BIOXRGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | 46.8% | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | 39.4% | 22.0% | ||
| Q4 24 | 42.0% | 22.8% | ||
| Q3 24 | 40.2% | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | 50.8% | 21.5% |
营业利润率BIOXRGR
| Q4 25 | — | 2.3% | ||
| Q3 25 | 9.3% | -2.7% | ||
| Q2 25 | — | -15.6% | ||
| Q1 25 | 1.5% | 6.2% | ||
| Q4 24 | 14.5% | 7.8% | ||
| Q3 24 | 2.5% | 3.1% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | 15.7% | 5.5% |
净利率BIOXRGR
| Q4 25 | — | — | ||
| Q3 25 | -9.6% | 1.2% | ||
| Q2 25 | — | -13.0% | ||
| Q1 25 | -2.6% | 5.7% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | -6.6% | 3.9% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | 11.6% | 5.2% |
每股收益（稀释后）BIOXRGR
| Q4 25 | — | $0.22 | ||
| Q3 25 | $-0.12 | $0.10 | ||
| Q2 25 | — | $-1.05 | ||
| Q1 25 | $-0.02 | $0.46 | ||
| Q4 24 | $0.00 | $0.62 | ||
| Q3 24 | $-0.10 | $0.28 | ||
| Q2 24 | — | $0.47 | ||
| Q1 24 | $0.14 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $288.3M | $283.8M |
| 总资产 | $734.9M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIOXRGR
| Q4 25 | — | $92.5M | ||
| Q3 25 | $15.5M | $80.8M | ||
| Q2 25 | — | $101.4M | ||
| Q1 25 | $38.5M | $108.3M | ||
| Q4 24 | $29.2M | $105.5M | ||
| Q3 24 | $32.3M | $96.0M | ||
| Q2 24 | — | $105.6M | ||
| Q1 24 | $16.4M | $115.3M |
股东权益BIOXRGR
| Q4 25 | — | $283.8M | ||
| Q3 25 | $288.3M | $279.6M | ||
| Q2 25 | — | $289.3M | ||
| Q1 25 | $345.0M | $321.5M | ||
| Q4 24 | $346.3M | $319.6M | ||
| Q3 24 | $346.0M | $314.9M | ||
| Q2 24 | — | $321.5M | ||
| Q1 24 | $348.5M | $332.0M |
总资产BIOXRGR
| Q4 25 | — | $342.0M | ||
| Q3 25 | $734.9M | $342.3M | ||
| Q2 25 | — | $349.5M | ||
| Q1 25 | $798.2M | $379.0M | ||
| Q4 24 | $835.2M | $384.0M | ||
| Q3 24 | $827.3M | $373.5M | ||
| Q2 24 | — | $376.7M | ||
| Q1 24 | $836.1M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | — | $12.3M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流BIOXRGR
| Q4 25 | — | $15.5M | ||
| Q3 25 | $14.4M | $12.9M | ||
| Q2 25 | — | $14.7M | ||
| Q1 25 | $23.3M | $11.1M | ||
| Q4 24 | $-5.4M | $20.0M | ||
| Q3 24 | $5.2M | $9.4M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | $-17.4M | $7.3M |
自由现金流BIOXRGR
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
自由现金流率BIOXRGR
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
资本支出强度BIOXRGR
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
现金转化率BIOXRGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | -8.85× | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | -1.78× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIOX
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
